U.S. markets closed

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.14-0.51 (-2.16%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close23.65
Open23.68
Bid20.20 x 1300
Ask23.15 x 2200
Day's Range23.14 - 23.75
52 Week Range10.18 - 31.27
Volume94,188
Avg. Volume195,207
Market Cap887.41M
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers
    Benzinga

    Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers

    Eli Lilly & Co’s (NYSE: LLY) R&D partner Merus N.V. (NASDAQ: MRUS) have revealed some new data at ASCO21 for an in-house program, zenocutuzumab (Zeno), in patients with NRG1+ cancers. As of April 13 cutoff date, Zeno induced partial responses in 13 of 45 patients, with an overall response rate of 29%. Merus is evaluating the candidate in a single-arm Phase 1/2 study with 61 enrolled patients. Notably, 12 of the evaluable patients came into the trial with NRG1 positive pancreatic cancer, with fiv

  • Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
    GlobeNewswire

    Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)

    - 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across several NRG1+ tumor types (29%)- Zenocutuzumab continues to be well tolerated with a favorable safety profile- Company to host investor call to discuss interim clinical results and provide a program update on

  • Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m. ET. The live webcast of the presentation will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time. About MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter. Investor and Media Inquiries: Kathleen FarrenMerus N.V.Communications Specialist617-230-4165k.farren@merus.nl